AgingResearch.NewsJoin free

Phase 1Recruiting

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

A Phase I Study of GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Participants With Selected Relapsed/Refractory GPNMB-Expressing Solid Tumours

Sponsor
Canadian Cancer Trials Group (Research network)
Enrolment
30 planned
Conditions
Alveolar Soft Part Sarcoma; Renal Cell Carcinoma; Triple Negative Breast Cancer
Interventions
Fludarabine; Cyclophosphamide; GCAR1
Ages
children, adults, older adults
Registry
NCT07297667

Full record on ClinicalTrials.gov

From the registry

Only enrolling in Canada. The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what effects GCAR1 has on selected cancers

Primary outcomes

  • To determine the recommended phase II dose (RP2D), defined as the next lower dose below the maximum administered dose, of GPNMB directed CAR T cell therapy

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Started

  5. Registered